Trial Profile
Safety, Efficacy, Tolerability and Pharmacokinetics of AGN-223575 Ophthalmic Suspension in Patients With Dry Eye Disease
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 07 Apr 2019
Price :
$35
*
At a glance
- Drugs AGN 223575 (Primary)
- Indications Dry eyes
- Focus Therapeutic Use
- Sponsors Allergan
- 23 Feb 2016 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov record.
- 07 Jan 2016 Planned number of patients changed from 168 to 236 as reported by ClinicalTrials.gov record.
- 07 Jan 2016 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov record.